Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Indications/Uses
Psychoses.
|
|
Dosage/Direction for Use
Adult: PO 25-600 mg/day in 2-3 divided doses. IM 25-200 mg/day.
|
|
Contraindications
Coma, CNS depression and phaeochromocytoma.
|
|
Special Precautions
Renal and hepatic impairment, CV disease, Parkinson's disease, epilepsy, depression, myasthenia gravis, prostatic hypertrophy, elderly, history of angle-closure glaucoma, severe respiratory disease, blood dyscrasias or history of jaundice. Photosensitisation may occur. May affect performance of skilled tasks. Gradual withdrawal after long-term therapy and monitor closely to avoid risk of acute withdrawal syndromes or rapid relapse. Pregnancy, lactation.
|
|
Adverse Reactions
Parkinsonian symptoms, dystonia, akathisia, tardive dyskinesia. Interference with temp regulation. CNS effects, GI disturbances, nasal congestion, antimuscarinic symptoms, CV symptoms, ECG changes, endocrine effects, blood dyscrasias, photosensitisation, contact sensitisation and rashes, jaundice, corneal and lens opacities, purplish pigmentation of the skin, cornea, conjunctiva and retina.
Potentially Fatal: Neuroleptic malignant syndrome. |
|
Drug Interactions
Increased risk of extrapyramidal adverse effects when used with SSRIs. May cause neuroleptic malignant syndrome or hyperpyrexia when used with chlorpromazine, levomepromazine or trifluoperazine.
|
|
CIMS Class
|
|
ATC Classification
N05AA06 - cyamemazine ; Belongs to the class of phenothiazine antipsychotics with aliphatic side-chain.
|
